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The management of cancer patients is frequently complicated by the occurrence of
cachexia. This is a complex syndrome that markedly impacts on quality of life as well as
on tolerance and response to anticancer treatments. Loss of body weight, wasting of both
adipose tissue and skeletal muscle and reduced survival rates are among the main features
of cachexia. Skeletal muscle wasting has been shown to depend, mainly at least, on the
induction of protein degradation rates above physiological levels. Such hypercatabolic
pattern is driven by overactivation of different intracellular proteolytic systems, among
which those dependent on ubiquitin-proteasome and autophagy. Selective rather than
bulk degradation of altered proteins and organelles was also proposed to occur. Within
the picture described above, the muscle is frequently considered a sort of by-stander
tissue where external stimuli, directly or indirectly, can poise protein metabolism toward
a catabolic setting. By contrast, several observations suggest that the muscle reacts
to the wasting drive imposed by cancer growth by activating different compensatory
strategies that include anabolic capacity, the activation of autophagy and myogenesis.
Even if muscle response is eventually ill-fated, its occurrence supports the idea that in the
presence of appropriate treatments the development of cancer-induced wasting might
not be an ineluctable event in tumor hosts.
Keywords: muscle wasting, protein turnover, energy metabolism, myogenesis, adaptive response, oxidative
stress
INTRODUCTION
Cachexia is a complex multiorgan syndrome that affects 50–80% of cancer patients and accounts
for about 20% of cancer deaths (Argilés et al., 2014). Characteristic features of this syndrome
are body weight loss, muscle wasting, adipose tissue depletion and metabolic abnormalities. The
main symptoms include anorexia, anemia, asthenia and fatigue, that eventually result in severely
impaired patient quality of life.
The pathogenesis of cancer cachexia is a complex phenomenon that includes nutritional
changes, hypoanabolism, the onset of an overall hypercatabolic response that mainly affects
proteins and lipids, chronic inflammation and altered energy metabolism. Last, but not least,
the standard of care of neoplastic disease generally includes chemotherapy, further complicating
the scenario. Indeed, cachectic patients very frequently cannot cope with anti-cancer treatment
schedule and often require dosage limitation and/or therapy interruption, reducing both drug
effectiveness and patient survival (Pin et al., 2018).
Several potential anti-cachexia drugs are currently being tested in clinical trials, but none of them
has proved effective enough to be routinely applied in the clinical practice (Morley et al., 2014). In
this regard, the small number of clinical trials and the poor knowledge about the pathogenesis of
cancer cachexia likely account for the lack of effective treatments (Penna et al., 2016b).
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The present review will discuss the mechanisms underlying
cancer-induced wasting and will focus on the adaptive response
set up by the skeletal muscle to the challenge posed by alterations
at the systemic level. In this regard, most of the existent studies
and reviews consider the skeletal muscle as a passive target
of stimuli that eventually lead to reduced anabolism and/or
increased catabolism. By contrast, muscle tissue attempts to strike
back by modulating metabolism in order to set up a sort of
defensive strategy against a hostile external environment. This
is particularly relevant since understanding and potentiating
such reactive behavior could improve the effectiveness of anti-
cachexia treatments.
MALNUTRITION
Cancer-associated malnutrition reflects into involuntary body
weight loss that results from the combination of several factors
such as reduced food intake, malabsorption, altered substrate
utilization and increased substrate demand. The occurrence of
malnutrition is highly unfavorable, since both recovery and
tolerance to antineoplastic treatments are definitely improved
in well-nourished than in malnourished subjects (e.g., with
unintentional body weight loss >5%). Being malnutrition a
potent predictor of bad outcome, the achievement of a good
nutritional state in cancer patients should become a goal to be
pursued in the clinical practice (Aversa et al., 2017). In this
regard, helpful guidelines for the management of malnutrition in
cancer patients have been set up by both the European Society of
Parenteral and Enteral Nutrition (ESPEN; Arends et al., 2017a)
and the Academy of Nutrition and Dietetics (AND; Thompson
et al., 2017). These documents include the need of an early
nutritional assessment, the relevance of nutritional counseling
during the course of the disease, the definition of an appropriate
and personalized nutritional support, the identification of the
right moment for the adoption of such support.
Nutritional habits in cancer patients can be affected very early,
resulting in latent malnutrition that becomes frankly evident
while the disease progresses, accompanying the appearance of
cachexia. Multiple mechanisms contribute to malnutrition, such
as tumor localization at the gastrointestinal tract, pain, anxiety,
malabsorption, and anorexia. While this latter is very often
recognized in cancer patients, in the early phases of disease it
happens to be underestimated and for this reason it might not be
promptly addressed. To circumvent this possibility, nutritional
behavior should be accurately assessed in all cancer patients at
first diagnosis (Arends et al., 2017b), in order to pick up and
evaluate even small changes from usual habits.
Humoral factors produced by the host as well as by the tumor
have been proposed to work in concert to modulate patient
nutritional behavior, affecting, directly or indirectly, the central
regulation of appetite. In this regard, several pro-inflammatory
cytokines have been shown to contribute to anorexia in cancer,
per se, but also enhancing the availability of neuropeptides
acting at the central nervous system level such as melanocortin,
neuropeptide Y, or leptin (Ezeoke and Morley, 2015). Particularly
relevant in this regard is ghrelin, an orexigenic hormone mainly
produced in the stomach, whose levels are usually increased in
cancer patients. Such increase could result from both an attempt
to counteract anorexia and the onset of ghrelin resistance (Argilés
et al., 2017). The resulting picture is the induction of signaling
pathways involved in causing anorexia at the expense of those
able to stimulate food intake, eventually leading to loss of appetite
and/or increased satiety (Argilés et al., 2014).
Despite reduced food intake is an important component
of body weight loss, nutrient availability being lower than
normal, cancer-associated malnutrition is quite different from
that occurring in subjects exposed to fasting or to caloric
restriction. Indeed, cancer patients very often are no more
able to appropriately modulate their metabolism to meet the
lack of nutrients. As an example, caloric restriction in healthy
subjects results in increased glucose and lipid mobilization,
sparing proteins as much as possible. By contrast, reduced food
intake in cancer patients is associated with random mobilization
of substrates, setting protein metabolism toward a persistently
negative nitrogen balance.
MUSCLE PROTEIN TURNOVER
The loss of muscle mass and function, one of the main features
of cancer cachexia, markedly impairs patient quality of life and
survival. In addition, muscle mass depletion has been associated
with reduced tolerance to anticancer treatments (Figure 1).
In addition, recent observations show that immunotherapy by
checkpoint inhibitors lose effectiveness in cachectic patients,
likely due to the establishment of primary resistance (Coss
et al., 2018). For these reasons, an accurate estimate of muscle
mass and quality should be pursued during the management of
cancer patients. By contrast, still nowadays the first evaluation
of a patient mainly takes into account parameters such as
body weight or body mass index (BMI), that do not provide
any information about body composition. Indeed, normal body
weight and/or BMI could result from increased adiposity or
tissue water content, de facto masking the occurrence of muscle
mass depletion.
Protein content, the most relevant component of muscle
mass, depends on the balance between rates of protein synthesis
and breakdown. Physiologically speaking, disruptions of
such equilibrium activate an adaptive response aimed at
reaching a new homeostasis that can alternatively result in
muscle hypertrophy or hypotrophy, respectively depending
on the prevalence of protein synthesis or degradation
(Argilés et al., 2014).
Protein Breakdown
Intracellular protein degradation in the skeletal muscle relies
on the activity of four main proteolytic pathways that depend
on calpains, caspases, lysosomes, and proteasome. Results
obtained in both experimental and clinical studies have clearly
demonstrated that muscle wasting in cancer hosts is associated
with supra-physiological activation of these proteolytic pathways
(Penna et al., 2014), with particular reference to those depending
on proteasome and lysosomes. These systems are involved in
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FIGURE 1 | Relevance of muscle wasting to cancer patient management. The occurrence of metabolic changes that result in muscle protein hypercatabolism and
impaired regeneration capacity negatively impinges on both patient quality of life and survival. ks = fractional rate of protein synthesis; kd = fractional rate of protein
degradation.
different aspects of intracellular protein degradation, the former
breaking down short-lived and regulatory proteins, the latter
being in charge of the disposal of altered organelles and structural
proteins (Penna et al., 2014).
The activity of the proteasome-dependent proteolytic
system depends on the availability of both ubiquitin and
enzymes involved in protein substrate ubiquitylation, namely
E1 (ubiquitin activating enzymes), E2 (ubiquitin conjugating
enzymes) and E3 (ubiquitin ligases). As for the E3 family, some
members are defined as muscle-specific. The most widely studied
are MAFbx/atrogin-1 and MuRF1/TRIM63. The former is in
charge of targeting proteins involved in cell cycle control, cell
differentiation and cell death, while the latter mainly marks for
degradation structural proteins (Argilés et al., 2014). The most
recently discovered member of the muscle-specific E3 family
is SMART (Milan et al., 2015). The expression levels of these
muscle-specific ubiquitin ligases have been accepted as molecular
markers of proteasome-dependent proteolysis and have been
demonstrated to increase in different experimental models of
cancer cachexia (Argilés et al., 2014). As for human studies,
several reports show that in cancer patients this proteolytic
system is activated above physiological levels. Of particular
relevance, such enhanced activity has been observed also in
non-weight losing gastric cancer patients (Bossola et al., 2003),
recalling the need of early assessment of cachexia. On the
other side, studies reporting unchanged levels of molecular and
biochemical markers pertaining to the ubiquitin-proteasome
proteolytic system in cancer patients do exist (Op den Kamp
et al., 2012; Tardif et al., 2013).
The involvement of lysosomal proteolysis in muscle wasting
is mainly referred to the overactivation of autophagy. This is a
physiological process in charge of degrading cellular components,
whose rate is increased by lack of nutrients or by the presence
of damaged organelles, such as mitochondria or peroxisomes.
Some years ago the discovery of autophagy-related (ATG) genes
has refreshed the field, providing useful tools to investigate the
process. Indeed, at least some of the proteins encoded by these
genes, such as beclin 1 and LC3B are now accepted markers of
autophagy. The physiological protein homeostasis in the muscle
is maintained by basal autophagy, in view of its role in the
routine clearance of wasting products such as altered proteins
and organelles. Disruption of autophagy has been shown to
be associated with progressive muscle derangements, such as
those occurring in mice lacking the Atg7 or the OPA1 genes
(Masiero et al., 2009; Tezze et al., 2017) or carrying the BCL2
AAA mutation (He et al., 2012). On the other side, markers
of autophagy are overexpressed in several muscle wasting-
associated states such as denervation and fasting, suggesting that
stress-induced autophagy is activated above physiological levels
in these diseases. Consistently, the induction of autophagy in
the skeletal muscle of both tumor-bearing animals and cancer
patients is demonstrated by several reports (Penna et al., 2013;
Tardif et al., 2013; Aversa et al., 2016; Pigna et al., 2016).
However, despite autophagic flux is increased, the process does
not reach its final step with complete cargo degradation, as
indicated by the observation that autophagosomes accumulate in
the muscle of cancer hosts, likely due to lysosomal engulfment
(Penna et al., 2013; Aversa et al., 2016; Pigna et al., 2016). On
the whole, these observations demonstrate that the relevance
of autophagy, enhanced or inhibited, to muscle wasting can
be significantly different, according to the specific situation.
In other words, both excessive and defective autophagy are
unwanted scenarios, and treatments impinging on these modality
of protein degradation should be aimed at maintaining/restoring
a physiologic autophagic flux.
Myofibrillar protein degradation depends on the preliminary
disruption of myofilaments. Such preventive cleavage cannot
be performed either by proteasome or lysosomes and has been
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proposed to involve other proteases, such as caspases and calpains
(Penna et al., 2014). Consistently, these latter are upregulated and
overactivated in the skeletal muscle of tumor-bearing animals
(Llovera et al., 1995; Costelli et al., 2002; Pin et al., 2017) and of
cancer patients (Smith et al., 2011).
Unfolded protein response (UPR) is important for the
maintenance of skeletal muscle mass in adults. Because PERK
regulates protein folding and calcium homeostasis, it is important
to investigate how these functions of PERK are affected in skeletal
muscle of smPERK-KO mice. How the activation of PERK
is regulated in conditions of muscle growth and atrophy and
whether modulation of its activity can improve skeletal muscle
mass in various catabolic states is also an important area of
future research.
Protein Synthesis
While the enhancement of muscle protein breakdown rates in
cancer cachexia is clearly demonstrated, the same does not apply
to protein synthesis, reduced, normal, or increased rates being
reported (Argilés et al., 2014). As for experimental cachexia,
the generally short time frame from tumor implantation and
animal death frequently results in impaired anabolic capacity, at
least in the skeletal muscle, although contrasting observations
have been reported. As an example, results obtained in mice
bearing the C26 or the LLC tumors show a reduction of muscle
protein synthesis rates, that cannot be restored by treatments able
to improve muscle mass (Toledo et al., 2016a; Nissinen et al.,
2018). On the other side, protein synthesis rates close to those of
controls have been observed in rats implanted with the Yoshida
AH-130 hepatoma (Costelli et al., 1993). Further variability can
be observed when tissues different from muscle are taken into
consideration. As an example, enhanced pro-synthetic capacity
has been measured in the liver of tumor-bearing animals, likely
due to the increased demand of acute phase proteins. These
observations put in evidence the limitations of the experimental
models, where cachexia frequently develops markedly faster than
in cancer patients.
The modulation of protein synthesis rates in cancer patients is
less clear. Some old studies, but also a recent one, have reported
that muscle protein synthesis is reduced in human pathology
(Emery et al., 1984; Hanson et al., 2017). By contrast, another
research group shows that pancreatic cancer patients are able
to improve baseline protein synthesis rates, that result poised
at values higher than those measured in healthy subjects (van
Dijk et al., 2015). Between these opposites, several studies report
muscle protein synthesis rates comparable to those of controls or
of non-weight losing cancer patients (Engelen et al., 2016).
Stimulation of muscle protein synthesis has been proposed
as a mean to improve muscle phenotype in cancer cachexia.
Most of the attempts, mainly unsuccessful, have involved
nutritional interventions or molecular tools aimed at improving
the muscle anabolic capacity. Indeed, advanced cancer patients
treated with both parenteral and enteral nutrition, including
or not the supplementation with amino acids, do not show
any improvement in muscle protein synthesis (Engelen et al.,
2016). Similar results have been obtained in studies attempting
to activate muscle protein anabolism by means of both drugs or
genetic tools (Costelli et al., 2006; Penna et al., 2010a). Recent
observations, however, show that there is the possibility to exploit
a sort of anabolic window in cancer patients (see below).
ENERGY METABOLISM
The vast majority of cancer patients are hypermetabolic,
presenting with resting energy expenditure (REE) higher than
normal (Vazeille et al., 2017). The underlying tumor-driven
mechanisms are still unclear, however released mediators and/or
pro-inflammatory stimuli rather than tumor burden, that is
usually quite low with respect to patient body weight (Purcell
et al., 2016), are likely involved. A recent study describes the
occurrence of hypermetabolism associated with body weight loss,
inflammation, altered energy balance and low performance status
in about 50% out of 390 cancer patients at first diagnosis, e.g., in
the absence of any anticancer treatment (Vazeille et al., 2017). As
stated above, metabolic alterations are an early feature in cancer
patients. Indeed, the study by Vazeille et al. (2017) shows that
about half of the hypermetabolic patients are non weight-losing
and present with good performance status. Consistently, normal
metabolism is rapidly restored in bladder cancer patients after
surgery, while body weight recovery is markedly delayed (Tobert
et al., 2017). These observations, coupled to those reported
above on skeletal muscle protein depletion, stress the need of
tools allowing an early detection of metabolic modulations in
cancer hosts.
Additional mechanisms leading to increased REE in cancer
patients may depend on alterations in thermogenesis. The tissues
mainly in charge of this process are the brown adipose tissue
(BAT) and the skeletal muscle. Both of them express high
amounts of uncoupling proteins (UCPs), whose levels have been
shown to further increase in tumor-bearing animals and cancer
patients (Collins et al., 2002; Bing, 2011). In the last few years,
white adipocytes have been proposed to convert into brown
adipocyte-like (beige) cells. This process, known as ‘browning,’
relies on increased UCP1 expression, resulting in a shift of
mitochondrial activity from ATP to heat production, increasing
both lipolysis and energy expenditure (Argilés et al., 2014).
In addition to increased expenditure, also reduced energy
production, due to undernutrition, decreased fat free mass
and low physical activity, participates to generate the negative
energy balance that frequently occurs in cancer patients. In
this regard, in the last few years particular emphasis has
been given to mitochondrial alterations occurring in the
skeletal muscle, these organelles being the main source of
energy production.
Muscle mitochondria in tumor-bearing animals show
ultrastructural alterations (Shum et al., 2012; Fontes-Oliveira
et al., 2013; Pin et al., 2015; Shum et al., 2018) associated
with uncoupling, leading to reduced oxidative capacity
(Julienne et al., 2012; Tzika et al., 2013). Such impairment
can be associated with the systemic inflammatory response
occurring in cachexia, as suggested by observations showing that
activation of the transcription factor NF-κB decreases muscle
oxidative capacity and down-regulates mitochondrial biogenesis
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(Julienne et al., 2012). In addition, altered mitochondrial
dynamics (fusion and fission) and biogenesis have been reported
in the ApcMin/+ mice, characterized by high circulating levels
of IL-6 (White et al., 2012). Moreover, mitochondria alterations,
in addition to impinge on energy production, also favor the onset
of oxidative stress, both working as catabolism-inducing stimuli.
OXIDATIVE STRESS
The intracellular sources of oxidative species such as reactive
oxygen and nitrogen species (ROS/RNS) are organelles such
as mitochondria and sarcoplasmic reticulum, and enzymes,
in particular the nicotinamide adenine dinucleotide phosphate
oxidase and the xanthine oxidase. The occurrence of oxidative
stress depends on an altered balance between the production
of ROS/RNS and the activity of the intracellular antioxidant
systems. An altered redox homeostasis may exert important
effects on the integrity of biological macromolecules, with
potential consequences on both cell survival and metabolism
(Gomez-Cabrera et al., 2009). In this regard, muscle wasting
in cancer hosts has been associated with increased ROS/RNS
levels and with enhanced oxidative damage to lipids and proteins
(Mastrocola et al., 2008; Sullivan-Gunn et al., 2011; Salazar-
Degracia et al., 2018). At the muscle level, these feature have
also been correlated with increased protein breakdown rates
as well as with the activation of the inflammatory response
(Gomes-Marcondes and Tisdale, 2002; Mastrocola et al., 2008;
Puig-Vilanova et al., 2015).
The increase of oxidative species in cachectic subjects may
rely on several mechanisms among which pro-inflammatory
cytokines, antineoplastic treatments and the loss of coupling
between phosphorylation and oxidation in mitochondria. As
reported above, several intracellular signaling pathways are
regulated, partially at least, by ROS/RNS. Particularly relevant are
those leading to activation of the redox-sensitive transcription
factors NF-κB and AP-1. The former, in particular, has been
shown to contribute to impaired myogenesis (see below) and
to enhance the expression of molecules pertaining to the
intracellular proteolytic machinery. In this regard, oxidative
stress has been proposed to impinge on the activation of
Ca2+-dependent proteolysis in the presence of Ca2+ overload,
on caspase-3 dependent induction of proteasome activity and
on up-regulation of muscle-specific ubiquitin ligases (Ábrigo
et al., 2018). Moreover, a lot of evidence suggests that also
autophagic degradation can be regulated by oxidative species,
mainly acting on signaling pathways dependent on p38 or
PI3K/Akt (Ábrigo et al., 2018).
Finally, redox homeostasis in the cell largely depends
on mitochondria ‘well-being.’ Indeed, altered or damaged
mitochondria fail to produce energy and may become both an
uncontrolled source of ROS and a target for such oxidant species.
The presence of altered mitochondria is an additional pro-
catabolic stimulus, resulting in activation of mitophagy. While
the goal of such activation is to get rid of useless organelles, the
result is a reduction of muscle mitochondria abundance, that
frequently in cachectic subjects is not associated with enhanced
mitochondrial biogenesis, also in view of the reduced energy
availability (Ábrigo et al., 2018).
CYTOKINES AND HORMONES
More than 150 years ago, Rudolf Virchow proposed that
carcinogenesis requires a pro-inflammatory milieu, mainly on the
basis that morphological analysis repeatedly reports infiltration
of the tumor stroma by inflammatory cells (Liu et al., 2017).
About one century later, the discovery of cytokines and of
the role that these mediators play in tumor progression has
provided an additional support to the relevance of inflammation
to carcinogenesis. In addition, the same mediators have been
shown to significantly contribute to the pathogenesis of cancer
cachexia (Argilés et al., 2014).
In the last two decades, cancer cachexia has been mainly
explained as the result of systemic inflammation (acute phase
response) due to the host response to tumor growth (Figure 2).
Several observations support such hypothesis. Indeed, in cancer
patients plasma levels of acute phase reactants, C reactive protein
in particular, are positively correlated with increased REE and
predict reduced survival rates. Along this line, circulating C
reactive protein levels contribute to build up the Glasgow
prognostic score (Fearon et al., 2006). To obtain the amino
acids necessary to synthesize the acute phase proteins, the liver
markedly impinges on muscle metabolism, leading to increased
protein degradation and, depending on the tumor, to reduced
protein synthesis rates. Finally, also the skeletal muscle of tumor-
bearing mice has been shown to express mRNAs coding for
several acute phase reactants (Bonetto et al., 2011), although the
real meaning of this expression pattern is still unknown.
The hypercatabolic setting that characterizes cancer cachexia
results, partially at least, from the complex interplay among
humoral mediators, including proinflammatory cytokines,
hormones and growth factors. Reciprocal regulations occur in
cancer hosts, cytokines being able to impinge on the hormonal
homeostasis and vice versa. High plasma levels of IL-6, TNFα,
and γ-INF have been observed in both tumor-bearing animals
and cachectic cancer patients (Tisdale, 2010). Several cytokines,
among which TNFα, have been shown to modulate peripheral
insulin sensitivity, with a mechanism that affects the activation
of the insulin receptor and of down-stream signaling molecules.
In addition, TNFα also down-regulates the signaling pathways
dependent on the insulin-like growth factor (IGF)-1, reducing
muscle anabolic capacity and enhancing the pro-catabolic
stimuli (Tisdale, 2010). Few years ago, TGFβ deriving from
bone resorption due to metastatic disease has been shown
to significantly contribute to cancer-induced muscle wasting
(Waning et al., 2015). Quite recently, TGF-β and TNFα have
been shown to mediate the expression of the zinc transporter
ZIP14, that is overexpressed in the skeletal muscle of both
cachectic tumor-bearing animals and patients affected by
metastatic cancer and that plays a causative role in muscle
wasting (Wang et al., 2018).
The relevance of cytokines to cachexia has been demonstrated
by studies showing that their administration to healthy animals
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FIGURE 2 | Humoral mediators of cancer cachexia. Humoral mediators differentially involved in the inflammatory response play a crucial, but probably not exclusive,
role in the pathogenesis of cancer cachexia.
results in skeletal muscle atrophy (Tisdale, 2010) as well as in
alterations of lipid metabolism associated with down-regulation
of lipoprotein lipase activity, induction of the hormone-sensitive
lipase and stimulation of hepatic lipogenesis (Tisdale, 2009). Most
of these effects also occur in tumor-bearing animals, and can
be prevented treating the animals with specific anti-cytokine
antibodies (Tisdale, 2009). Despite these observations, however,
there is still no clear-cut evidence that anti-cytokine strategies can
be useful to manage cachexia in cancer patients.
In addition to acute phase reactants, hormones and cytokines,
other mediators have been proposed to contribute to the onset
and progression of cancer cachexia. As an example, fat-derived
leptin has been shown to inhibit both food intake and adipose
tissue mass in healthy animals, although its circulating levels do
not increase in both cancer patients and tumor-bearing animals,
suggesting that its role in cachexia is not a causative one (Argilés
et al., 2014). Among the mediators possibly involved in causing
adipose tissue depletion in cachexia, the lipid mobilizing factor,
increased in the circulation of cachectic cancer patients (Bing,
2011), has been shown to induce triglyceride disassembly by
stimulating the activity of both the adipose triglyceride lipase
and the hormone sensitive lipase, and to upregulate UCP2
expression in liver and muscle (Bing, 2011). Several reports have
shown that the expression of myostatin, a molecule belonging
to the TGFβ family and endowed with inhibitory activity on
muscle enlargement, is enhanced in the muscle of tumor-bearing
animals, although its relevance to muscle wasting in cancer
hosts has not been completely defined. In this regard, recent
observations show that myostatin can be secreted by the BAT,
leading to impaired mTOR signaling in fast myofibers. As a
result, the expression levels of several proteins, among which
components of the mitochondrial electron transport chain, are
reduced, affecting the energy balance (Kong et al., 2018). Several
observations report the causal involvement of other TGFβ family
members such as activins, and on the basis of these findings,
drugs able to interfere with the activin receptor, which is
also shared by myostatin, are currently under investigation as
potential tools to manage cancer cachexia (Hatakeyama et al.,
2016; Nissinen et al., 2018).
Recent reports suggest that receptors of the Toll-like family
(TLRs) can be involved in mediating muscle wasting in
cancer cachexia. In particular, TLR4 appears to directly activate
muscle protein breakdown in mice hosting the Lewis lung
carcinoma. Consistently, TLR4 inhibition exerts a protective
effect against muscle wasting, likely by reducing the production
of pro-inflammatory cytokines such as TNFα and IL-6 (Zhang
et al., 2017a). In addition, the activation of TLR4 has also
been shown to depend on Hsp70 and Hsp90 that reach
the muscle through exosomes released by the tumor (Zhang
et al., 2017b). Similarly, the activation of TLR7 by miR-21
contained into tumor-derived extracellular vesicles has been
proposed to trigger apoptosis in cultured myoblasts, potentially
contributing to the defective myogenesis reported in cancer
cachexia (He et al., 2014).
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MYOGENESIS
Myogenesis is a physiological process induced during embryonal
development and susceptible of activation in the adult after
skeletal muscle injury, where it is more properly defined
as regeneration. Irrespective of the trigger, muscle fiber
degeneration following damage implies the recruitment and
activation of satellite cells, stem cells resident in the muscle
underneath myofiber basal lamina, that proliferate and fuse
with existing fibers to restore the original muscle mass. When
regeneration is triggered by chronic pathologies such as muscle
dystrophies, satellite cell pool can be exhausted, leading to
substitution of muscle with connective tissue.
The amount of satellite cells is not the same in every
muscle type. As an example, it is higher in oxidative than
in glycolytic muscles, respectively characterized by slow and
fast contraction (Yin et al., 2013). In addition, satellite cell
population is heterogeneous in terms of both myogenic potential
and ability to perform the asymmetric division, the hallmark of
stemness. In addition to satellite cells, several other cell types
have been recognized as endowed with myogenic potential, such
as mesoangioblasts and PW1+ cells. Finally, an important role
during myogenesis/regeneration is played by fibroadipogenic
progenitors (FAPs), cells that are unable to differentiate to muscle,
but that are crucial to sustain myogenic precursors during
proliferation and differentiation (Costamagna et al., 2015).
The activation of myogenesis in the adult strictly relies
on modulations of the muscle microenvironment, that are
different depending on the regenerative stimulus, e.g., acute
damage or chronic diseases. Particularly relevant, in this regard,
are the interactions occurring among immune cells, humoral
mediators and myogenic precursors. Indeed, the recruitment
of pro-inflammatory (M1) macrophages in the injured muscle
is concomitant with satellite cell activation. However, the
subsequent step of myogenic differentiation (satellite cell fusion
with existing myofibers) strictly requires the induction of M1
cell apoptosis and their replacement with anti-inflammatory
(M2) macrophages (St Pierre and Tidball, 1994). This transition
must take place with an accurate timing (M1: 1–2 days post-
injury; M2: 4 days post-injury) in order to ensure damage
repair and the down-regulation of injury-induced inflammatory
response. A crucial role in such process is played by cytokines,
produced by macrophages but also deriving from other cellular
sources. The production of TNFα and IL-10 allows the shift
from pro-inflammatory to anti-inflammatory milieu, killing FAPs
and M1 macrophages and allowing the recruitment of M2 cells
(Perdiguero et al., 2011; Fiore et al., 2016). In addition, IL-
10 also promotes the differentiation of myogenic precursors
different from satellite cells (Bosurgi et al., 2012). If cytokine
production does not conform to the correct regeneration
schedule, however, the process can be markedly impaired. As an
example, if TNFα is produced earlier than days 3–4 post-injury,
regeneration is impaired due to persistently cycling satellite cells
(Guttridge et al., 2000; Bakkar et al., 2008). The other way
round, if TNFα is not produced at the right moment, FAPs will
not die and, taking advantage of anti-inflammatory cytokines
such as IL-10 and TGFβ, will result in the overproduction
of extracellular matrix, eventually leading to muscle fibrosis
(Fiore et al., 2016).
Alterations in the regenerative process have been proposed
to contribute to muscle wasting occurring in several chronic
diseases such as dystrophies, myopathies, autoimmune diseases,
and cancer. Focusing on this latter, experimental studies
performed in mice hosting the C26 tumor have shown in the
muscle increased expression of Pax7, a marker of satellite cell
activation, and reduced levels of myogenin, an indicator of
ongoing differentiation. Similar observations have been reported
in cancer patients (Ramamoorthy et al., 2009; Penna et al.,
2010b; He et al., 2013). Consistently, in vivo regeneration is
delayed in the muscle of tumor-bearing mice, with a mechanism
that has been proposed to involve a persistent activation of the
transcription factor NF-κB (He et al., 2013), and the increased
phosphorylation of the stress kinase ERK (Penna et al., 2010b).
Recent observations have shown that overexpression of
Twist1, a transcription factor associated with the malignant
progression of several tumors, in myogenic precursors leads
to skeletal muscle hypotrophy. Such a pattern is associated
with increased myostatin expression in Twist1+ satellite cells.
The authors hypothesize that in satellite cells Twist1 drives
both myostatin synthesis and secretion. The released myostatin
targets myofibers that respond by increasing Twist1 expression,
resulting in muscle wasting (Parajuli et al., 2018). Of interest,
Twist1 levels higher than in healthy mice have been observed
in the skeletal muscle of animals bearing different experimental
tumors. Not only, if Twist1 expression is abrogated in satellite
cells of tumor hosts, cancer-induced muscle wasting appears
prevented (Parajuli et al., 2018). Finally, the zinc transporter
ZIP14, recently shown to contribute to muscle wasting in cancer
hosts, has also been proposed to interfere with regeneration, since
it is induced in satellite cells isolated from cachectic muscles.
Consistently, differentiation is impaired in ZIP14 overexpressing
C2C12 myoblasts in the presence of zinc (Wang et al., 2018).
THE SKELETAL MUSCLE STRIKES
BACK: ADAPTIVE MECHANISMS TO
FACE THE WASTING DRIVE
Looking at the history of skeletal muscle biology, it is quite
evident that while the relevance of this tissue to the organism
life has been understood very early, for quite a long time the
muscle has been considered as a sort of protein-containing black
box, that receives nutrients, oxygen and signals from outside and
returns the contractile activity necessary for breathing, moving,
heart beating, etc. Only in the last few decades the idea that
the skeletal muscle is indeed a metabolically active tissue able
to release mediators and to influence, directly or indirectly,
other body compartments has been gaining a growing consensus.
However, still nowadays, when pathological muscle wasting is
addressed, the general approach is to take into consideration,
mainly at least, only alterations that take place in the extra-muscle
body compartments and that target the muscle. This occurs, for
example, when cancer-induced systemic inflammation and/or
malnutrition are evoked to explain muscle wasting in cachexia.
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For sure, the role played by these features is overall recognized;
what is lacking to this picture, however, is the response set up
by the muscle to the systemic alterations. The general view,
in this regard, is that the muscle passively suffers this sort of
‘aggression’ coming from the extra-muscle environment, being
unable to face the external catabolic stimuli that eventually
lead to the loss of muscle mass and function. However, several
evidence suggest that the skeletal muscle is indeed able to set
up compensatory, although eventually unsuccessful, strategies
attempting to counteract cancer-induced hypercatabolism and
hypoanabolism. Along this line, understanding these strategies
will be highly valuable in order to design protocols aimed to
support the muscle in the struggle against the wasting drive.
Muscle Anabolic Response
The above reported concept that slimming in cachexia is
different from that due to caloric restriction is based on the
observation that the latter is adopted in a physiological metabolic
environment, while the former occurs in the presence of marked
abnormalities, such as inflammation and hypermetabolism. In
particular, cancer hosts might not properly activate protein
synthesis following an increased nutrient loading, a condition
that has been defined as ‘anabolic resistance.’ Its occurrence
seriously questions the usefulness of anabolism-promoting
strategies: if the patient cannot activate protein synthesis, no
nutritional or pro-anabolic intervention will ever be successful.
In the last few years, however, the idea that cancer hosts
still maintain the ability to activate anabolism, at least until
cachexia does not reach the refractory stage, has gained a
growing consensus (Prado et al., 2013; Engelen et al., 2016;
Antoun and Raynard, 2018).
Several observations derived from both experimental and
clinical studies support this hypothesis. Muscle wasting in tumor-
bearing animals is unexpectedly associated with unchanged or
increased levels of molecules involved in the protein synthetic
machinery. As an example, the PI3K-Akt-mTOR signaling is
poised toward activation in mice implanted with the C26
tumor (Penna et al., 2010a), while protein synthesis rates are
unchanged with respect to controls in rats hosting the Yoshida
AH-130 hepatoma or the MCA sarcoma (Tessitore et al.,
1987; Stallion et al., 1995). As for human pathology, habitual
myofibrillar protein synthesis rates in gastric cancer patients,
either weight stable or weight losing, have been reported to
be comparable to control subjects (MacDonald et al., 2015).
Consistently, in the muscle of cancer patients, the pAkt/Akt
ratio and the levels of pGSK3β, both molecular markers of
an intracellular pro-anabolic setting, are comparable to control
levels or even increased (Aversa et al., 2012; Stephens et al.,
2015). A study performed on patients affected by non-small
cell lung cancer has shown the activation of a normal anabolic
response after an euglycemic, hyperinsulinemic clamp associated
with amino acid supplementation (Winter et al., 2012). Similarly,
a significantly high anabolic response independent from body
weight loss, muscle mass depletion and the occurrence of
inflammation, has been obtained feeding lung cancer patients
with an essential amino acid integration (Engelen et al., 2015).
Finally, the association of conventional nutritional support with
high leucine, fish oil and carbohydrate supplementation has
enhanced the muscle anabolic response in advanced cancer
patients (Deutz et al., 2011). On the whole, these observations
support the idea that, if adequately supported, cancer patients
might benefit from timely adopted nutritional, better if protein
enriched, interventions.
In addition to the supply of amino acids, mainly mere
‘bricks’ to build up new proteins, nutritional supplements can
also be useful in order to modulate both muscle and extra-
muscle environments. This applies, for example, when molecules
able to reduce inflammation are included in the nutritional
formula. Polyunsaturated fatty acids (PUFAs) belonging to the
ω-3 series have revealed promising in this regard: a recent
meta-analysis based on the screening of a huge number of
clinical trials involving chemotherapy-treated cancer patients has
shown that oral nutritional supplementation exerts beneficial
effects only when ω-3 PUFAs are included in the formulation
(de van der Schueren et al., 2018). It is still debated if ω-
3 PUFA supplementation also results in improved patient
outcome. While several studies support such possibility (reviewed
in Laviano et al., 2018), contrasting evidence do exist. In
this regard, no improvement of overall survival has been
reported in a study investigating the effects of ω-3 PUFA
supplementation in cachectic gastrointestinal cancer patients
treated with chemotherapy (Shirai et al., 2017).
Strategies aimed at counteracting members of the TGFβ
family such as myostatin and activin have been tested.
Particularly interesting appear the studies involving soluble
activin receptor type IIB and antibodies directed against the
activin II receptor (Bimargumab). In tumor-bearing mice the
former has been reported to increase survival and muscle wasting
as well as to improve the anabolic and anti-catabolic effect of
formoterol (Toledo et al., 2016b; Nissinen et al., 2018). Similarly,
Bimagrumab has proved effective in preventing muscle atrophy
induced by glucocorticoids or cancer (Lach-Trifilieff et al., 2014;
Hatakeyama et al., 2016). Clinical studies have been performed
or are currently ongoing in order to test humanized antibodies
targeting the activin IIB receptor. At present, the results available
demonstrate that lean mass and muscle strength are increased in
antibody-receiving volunteers (Becker et al., 2015).
Another exploitable strategy to improve anabolism is the
administration of ghrelin. In this regard, increased circulating
ghrelin markedly modulates protein and energy metabolism
(Ezquerro et al., 2017). Consistently, tumor-bearing animals
treated with ghrelin show increased food intake, improved body
composition and increased tolerance to anti-cancer drugs (Graf
and Garcia, 2017). Since ghrelin administration might also exert
undesirable effects, ghrelin analogs have been produced and are
currently studied in clinical trials. Among the most promising,
anamorelin has been shown to improve body composition and
muscle function in non-small cell lung cancer patients (Takayama
et al., 2016). By contrast, other studies have clearly shown that
anamorelin fails to improve motor function in cancer patients
(Temel et al., 2016), likely suggesting that muscle function cannot
be rescued by adopting single agent pharmacological strategies.
Subsequent investigations have shown that, in selected groups
of patients, anamorelin also leads to improved performance
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status (Katakami et al., 2018). Other appetite stimulants such as
macimorelin and a synthetic human ghrelin are actually under
investigation (Argilés et al., 2017).
Enhanced Intracellular Protein
Breakdown as a Salvage Pathway
An adequate protein homeostasis, e.g., a balance between protein
synthesis and degradation rates, is required to properly maintain
cell functions and to prevent the onset and progression of
diseases. In this regard, the observation that protein catabolism is
generally increased in several conditions associated with muscle
mass depletion, including cancer cachexia, has characterized
this arm of protein metabolism with a negative connotation.
However, normal cell function cannot disregard the presence
of an adequate rate of protein turnover, meaning that the
production of new proteins must be paralleled by the disassembly
of pre-existing damaged or misfolded proteins. This is true in
the whole organism and in the muscle in particular, where
several myopathies arise due to the absence of physiological
levels of protein catabolism (Bell et al., 2016). Indeed, the
physiological rate of protein degradation in the skeletal muscle is
considerably high, provided that this tissue is constantly exposed
to damaging events such as mechanical stretch, force generation,
and oxidative stress.
The observation that muscle intracellular proteolytic systems
are activated above physiological levels in cancer cachexia
(see above) has provided the basis for different experimental
approaches aimed at contrasting the onset and progression of
muscle mass depletion. As an example, genetic inhibition of
muscle-specific ubiquitin ligases has been shown to effectively
counteract the loss of muscle proteins (Rom and Reznick, 2016).
Such an approach, however, has not yet been validated for
the clinical use. Another tool has come from the discovery of
rather specific proteasome inhibitors such as bortezomib. While
this drug is widely used to treat hematologic malignancies,
studies performed on experimental models of cancer cachexia
have demonstrated that specific proteasome inhibition does
not improve muscle phenotype (Penna et al., 2016a). The lack
of effectiveness of the pharmacological approaches aimed at
counteracting proteasome-dependent proteolysis likely depend
on the compensatory activity set up by the other intracellular
proteolytic systems, further supporting the idea that if muscle
protein breakdown is overactivated in cancer cachexia, this does
not happen by chance. In other words, such activation above
physiological levels is likely part of an adaptive response due to
the steadily increased abundance of damaged/unwanted proteins,
ultimately aimed at maintaining vital functions. In this regard,
targeting the mechanisms leading to protein alteration rather
than protein degradation systems should be pursued.
Particularly relevant in terms of protein homeostasis
maintenance is the proteolytic system that relies on autophagy.
Enhancement of the autophagic-lysosomal protein degradation
has been demonstrated in several conditions characterized by
muscle wasting, including myopathies and cancer cachexia
(Penna et al., 2014), suggesting that limiting the activation of
this proteolytic system could be the goal to achieve in order to
prevent or at least delay the loss of muscle mass and function.
Such interpretation, however, does not take into account the
physiological relevance of autophagy. In this regard, observations
performed on experimental animals genetically manipulated
in order to obtain a muscle-specific autophagy-defective
phenotype have clearly shown that autophagy is required to
maintain a correct muscle morphology, a healthy mitochondrial
compartment and a proper force-generating capacity (Masiero
et al., 2009). Consistently with these observations, gene strategies
aimed at silencing Beclin-1, a key player of autophagosome
formation, have proved ineffective in preventing the reduction of
myofiber atrophy in mice hosting the C26 tumor (Penna et al.,
unpublished). In addition, frankly cachectic C26-bearing mice
treated with pharmacological inhibitors of the autophagic flux
do not survive (Penna et al., 2013). This observation suggests
that autophagy in the muscle of the C26 hosts is activated above
physiological levels also in order to provide substrates that are
no more available from the usual sources. In this regard, at a
certain point at least, such overactivation becomes an adaptive
response that is crucial to maintain the body homeostasis or to
support a new homeostatic level in stressful conditions. Partially
consistent with these observations are the results reported by
a study showing that stimulation of stress-induced autophagy
obtained through mTOR inhibition improves muscle phenotype
in tumor hosts (Pigna et al., 2016). However, long term treatment
with mTOR inhibitors in patients has been shown to result in
muscle wasting (Gyawali et al., 2016). Finally, overactivation
of autophagy obtained through TP53INP2/Dor overexpression
was shown to exacerbate the loss of muscle mass observed in
experimental diabetes, confirming that both direct inhibition and
stimulation of autophagy are detrimental in wasting conditions
(Sala et al., 2014).
On the whole, these observations support the idea that
modulations of autophagy can be good treatment options to
manage muscle wasting in cancer cachexia only if they succeed
in maintaining the physiological flux. In other words, too less
autophagy is as detrimental as too much autophagy. Finally, the
observation reported above clearly define that the prevention
or delay of the onset and progression of muscle wasting in
cancer cachexia cannot be obtained by targeting one specific
proteolytic system. By contrast, acting on the mechanisms that
activate the hypercatabolic drive appears a more promising
strategy. Just as an example, β2-adrenergic agonists have been
demonstrated to effectively improve muscle phenotype in tumor-
bearing animals as well as in cancer patients (Busquets et al.,
2004); such protection is associated with down-regulation of both
proteasome activity and autophagy (Penna et al., unpublished).
The regulation of protein hypercatabolism in muscle wasting
has also been associated with the activation of the UPR due to
endoplasmic reticulum (ER) stress (Afroze and Kumar, 2017; Ma
et al., 2017). Indeed, increased expression of ER stress markers
has been reported in denervated muscles (Yu et al., 2011) as well
as in the muscle of tumor-bearing animals (Bohnert et al., 2016).
Such a response has been proposed to reflect a compensatory
mechanism, since inhibition of both ER stress and UPR results
in the induction of muscle wasting, the more so when the muscle
is already depleted (Afroze and Kumar, 2017). More recently,
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FIGURE 3 | Muscle compensatory mechanisms activated in response to tumor growth. The skeletal muscle is a plastic tissue able to autonomously respond to the
wasting stimuli in order to maintain the homeostasis. Muscle loss occurs as a consequence of the failure to adapt to the alterations induced by the tumor.
Anti-cachexia drugs targeting specific cellular and molecular processes will boost the muscle adaptation potential, counteracting the wasting process.
evidence suggesting the relevance of the PERK arm of the
unfolded protein response to the maintenance of muscle mass
and function has been reported (Gallot et al., 2018).
Oxidative Stress Management
Oxidative species such as ROS and RNS have been involved in
the pathogenesis of cancer-induced muscle wasting (see above).
Along this line, antioxidant compounds such as vitamins C and
E, α-lipoic acid, N-acetylcysteine, and polyphenols have been
proposed as useful therapeutic tools. Polyphenols, in particular,
have been shown to protect against the onset of cachexia in
different types of tumors (Oelkrug et al., 2014; Gil da Costa
et al., 2017), likely due to their inhibitory effect on NF-κB (Gil
da Costa et al., 2017). On the other side, several pre-clinical
and clinical studies have demonstrated that the anti-cachectic
effects exerted by anti-oxidant drugs are poor, if not frankly
detrimental (Busquets et al., 2007; Assi et al., 2016). In this regard,
depending on the body compartment, tumor included, a pro-
oxidant environment can be either detrimental or beneficial and
anti-oxidant treatments can be helpful and exert unwanted effects
at the same time.
Both systemic mediators and intramyofiber events, such
as proinflammatory cytokines and mitochondrial alterations,
respectively, can generate a pro-oxidant environment in the
skeletal muscle of cancer hosts. However, even when muscle mass
and function are significantly reduced with respect to control
values, the tissue is able to activate an effective antioxidant
response. Indeed, increased mRNA expression of both Cu/Zn
SOD and catalase, associated with unchanged levels of protein
carbonylation and malondialdehyde, can be observed in the
muscle of C26-bearing mice (Assi et al., 2016; Ballarò et al.,
unpublished). Such antioxidant response is further enhanced
when tumor-bearing animals are exposed to a moderate exercise
protocol, that also results in improved muscle mass and function
(Ballarò et al., unpublished).
These results suggest that, despite profound metabolic
alterations occur in the muscle of cancer hosts, this tissue is still
able to activate and maintain an efficient anti-oxidant response,
suggesting that tissue-specific interventions able to improve
such adaptation would be beneficial to prevent or delay the
progression of cachexia toward the refractory phase.
Activation of the Myogenic Response
Physiologically, the skeletal muscle activates the regeneration
program to face myofiber injury. Previous observations have
reported that this process is activated in the skeletal muscle of
cancer hosts (see above), however, what is actually triggering
regeneration in this situation is still debated. In this regard, few
studies suggest that alterations of the dystrophin glycoprotein
complex leading to sarcolemma leakage play a crucial role
(Acharyya et al., 2005; He et al., 2013). However, the observation
that an inflammatory infiltrate is lacking in the muscle of tumor-
bearing animals (Berardi et al., 2008) does not support this
hypothesis. Another possibility is that the activation of the
regenerative response is another face of the residual anabolic
capacity reported in the muscle of cancer hosts. According to
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this possibility, but with unknown mechanisms, the muscle could
react to the hypercatabolic state by recruiting and activating
myogenic precursors, attempting to counteract the loss of muscle
proteins. Such a strategy is however ineffective, since for unclear
reasons committed Pax7+ myogenic precursors do not reach the
complete differentiation and accumulate in the muscle without
proceeding to fuse with existing myofibers. Consistently with
this hypothesis, treatments able to release the impairment of
myogenesis, such as MEK inhibitors or Pax7 silencing, also result
in improved muscle mass and function (Penna et al., 2010b;
Prado et al., 2012; He et al., 2013; Talbert et al., 2017).
Very little is known about the mechanisms that impair
complete myogenic differentiation in the muscle of cancer
hosts. The first possibility is that something has changed in
muscle stem cells, leading to altered differentiation capacity.
However, myogenic precursors isolated from the muscle of
C26-bearing mice have been shown to perfectly differentiate
in vitro (He et al., 2013; Inaba et al., 2018; Costamagna
et al., unpublished data), demonstrating that the impaired
regeneration does not depend on a cell autonomous defect.
Taking into consideration these results, a possible alternative
is that the presence of the tumor results in the generation
of a muscle microenvironment that is not permissive for
complete regeneration. Along this line, the persistently
increased activation of both ERK and NF-κB (see above)
are likely part of the mechanism that modulates muscle
microenvironment. An additional mechanism can rely on the
reduced recruitment to the muscle of neutrophils, macrophages,
and mesenchymal progenitors occurring in tumor-bearing
animals (Inaba et al., 2018).
Basal autophagy is also required to ensure both the
maintenance of satellite cell homeostasis and a proper
muscle regenerative response. Indeed, autophagy is steadily
activated in quiescent satellite cells in order to get rid of
potentially dangerous wasting products, preserving cell ‘well-
being.’ Defective autophagy results in satellite cell senescence,
mainly due to the accumulation of altered mitochondria
that leads to oxidative stress, eventually reducing both the
stem cell pool and function. Senescent muscle stem cells are
unable to be recruited and activated in response to damaging
stimuli (Sousa-Victor et al., 2018). Such pattern can be
reversed by restoring basal flux of autophagic degradation
or by pharmacological inhibition of ROS release above
physiological levels (García-Prat et al., 2016). In addition,
in the regenerating muscle autophagy has been proposed to
impinge on myoblast differentiation (Fiacco et al., 2016; Fortini
et al., 2016). Last but not least, autophagy is responsible for
providing activated satellite cells with nutrients required to
sustain the increased demand to exit quiescence and entering
the cell cycle (Tang and Rando, 2014). Consistently with this
hypothesis, the reduced expression of TP53INP2/DOR in the
skeletal muscle of tumor-bearing mice and cancer hosts (Penna
et al., unpublished) suggest that indeed basal autophagy is
reduced in these conditions, potentially impinging also on
Pax7+ cells.
The activation of satellite cells is characterized also by
modulations in the oxidative pattern. Quite recent studies show
that genetic manipulation of Pitx2 and Pitx3 transcription factors,
known to regulate the redox homeostasis during embryonal
myogenesis also affects the differentiation of adult satellite cells.
In particular, muscle regeneration fails in animals depleted of
both factors, that are characterized by markedly increased ROS
levels (L’honoré et al., 2018). The same study reports that,
while ROS increase is required by satellite cell to exit from
quiescence and to proceed toward differentiation, excess ROS
is detrimental (L’honoré et al., 2018). Along this line, reduced
oxidative potential has been reported in satellite cells isolated
from muscle biopsies of cancer patients, that are also endowed
with reduced ability to differentiate (Brzeszczyn´ska et al., 2016).
There is the possibility that the same alteration of redox state
applies to myogenic precursors isolated from tumor-bearing
animals, partially explaining the impaired regenerative response
(Penna et al., 2010b; He et al., 2013). On the other side, the
oxidative stress reported in the muscle of cancer hosts could also
reflect the attempt to generate an environment permissive for
satellite cell activation and differentiation.
CONCLUSION
Cancer cachexia arises from a complex milieu in which several
factors such as metabolic alterations, malnutrition and systemic
inflammation play a crucial role. Since this multiorgan syndrome
is an important challenge in patient management, the definition
of markers suitable to allow its early identification is actively
pursued for therapeutic purposes.
Several reviews analyzed the therapeutic strategies actually
available to counteract cancer cachexia (Advani et al., 2018;
Di Girolamo et al., 2018; Solheim et al., 2018); while quite
different approaches are adopted, all the studies agree in
stating that they are far from being effective, likely because
the mechanisms underlying this syndrome are only partially
elucidated. Particularly relevant in this regard, is the observation
that target tissues such as the skeletal muscle are able to
react to the wasting stimuli activating compensatory responses
(Figure 3). These counteractive strategies, however, are not
potent enough and do not succeed in preventing the progression
of cachexia. Along this line, the multimodal therapeutic protocol
to treat cachexia could take advantage also of new approaches
that, relying on understanding tissue-specific compensatory
responses, contribute to support the organism effort in defeating
the wasting drive.
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